PEPICELLI v. INNOCOLL HOLDINGS PUBLIC LIMITED COMPANY

CourtDistrict Court, E.D. Pennsylvania
DecidedMarch 10, 2022
Docket2:17-cv-00341
StatusUnknown

This text of PEPICELLI v. INNOCOLL HOLDINGS PUBLIC LIMITED COMPANY (PEPICELLI v. INNOCOLL HOLDINGS PUBLIC LIMITED COMPANY) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
PEPICELLI v. INNOCOLL HOLDINGS PUBLIC LIMITED COMPANY, (E.D. Pa. 2022).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

CIVIL ACTION IN RE INNOCOLL HOLDINGS PUBLIC _ : LTD. CO. SEC. LITIG. : : No. 17-341

MEMORANDUM PRATTER, J. MARCH 10, 2022 Shareholders sued Innocoll Holdings Limited, a pharmaceutical company, claiming that, in violation of the Securities and Exchange Act of 1934, Innocoll misrepresented its new product’s chances of success in the FDA approval process. The parties have now negotiated a settlement, and the named plaintiffs request that the Court certify a settlement class and preliminarily approve the setflement agreement. Because the proposed settlement appears fair, reasonable, and equitable, the Court grants their requests. BACKGROUND Innocoll, a pharmaceutical company that specializes in collagen technologies, went public in July 2014, That month, it announced that it would begin clinical trials for XaraColl, a collagen implant that contains pain medicine and is placed in surgical sites to relieve post-surgery pain. Two years later, Innocoll announced the results of the clinical trials and said that it planned to file anew drug application with the FDA. Innocoll filed that application but, nearly two months later, issued a press release explaining that the FDA had refused to accept the application for XaraColl. Innocoll had tested and submitted XaraColl as a drug, but the FDA claimed XaraColl should have been tested and submitted as a drug/device combination. The day after this announcement, the Innocoll share price plummeted by 61%.

Shareholders sued Innocoll, its CEO, and its Chief Medical Officer for violations of the Securities Exchange Act of 1934, claiming that they had misled investors who relied on the company’s positive statements about the product and its chances of FDA approval. The first complaint was dismissed, but upon the filing of the amended complaint, the parties proceeded to discovery. Midway through extensive discovery, the shareholders moved for class certification. Just before the certification hearing, the parties announced that they had negotiated a settlement: Innocoll will pay $2.755 million to shareholders, and in exchange, the shareholders will release all claims against Innocoll that arise out of the alleged misrepresentations. Based on this settlement, the lead plaintiffs, through counsel, have filed an unopposed motion for certification of the settlement class, preliminary approval of the settlement, and approval of the proposed notice. Having held a hearing on the motions, the Court grants them ail. LEGAL STANDARDS . Class actions “may be settled ... only with the court’s approval.” Fed, R. Civ. P. 23(e). Before approving of a class settlement, courts must follow a two-step process. First, the court holds

a preliminary approval hearing. If the court had not previously certified a litigation class, the court must decide whether to preliminarily certify the proposed settlement class. See In re Gen. Motors Corp. Pick-Up Truck Fuel Tank Prods. Liab, Litig., 55 F.3d 768, 800 (3d Cir, 1995). The court must also assess the settlement itself and the plan for notifying class members of it. See id. at 804— 05. In doing so, the court looks out for “any obvious problems.” Leap v. Yoshida, No. 14-cy-3650, 2015 WL 619908, at *2 (E.D. Pa. Feb. 12, 2015). Once the class members have been notified and given a chance to file claims or opt-out of the class and settlement deal, the court holds a final approval hearing. There, class members may voice objections, and the court will consider several

additional factors in deciding whether to grant final approval to the settlement. Jn re Linerboard Antitrust Litig., 292 F. Supp. 2d 631, 638 (E.D. Pa, 2003). DISCUSSION I. The Court preliminarily certifies the settlement class To have a class settlement, there must first be a class. Jn re Gen. Motors, 55 F.3d at 800, The proposed class must be ascertainable, such that the class members can be clearly identified. Byrd v. Aaron’s Inc., 784 F.3d 154, 163 (3d Cir. 2015). The proposed class must also satisfy the four prerequisites: numerosity, commonality, typicality, and adequacy. Fed. R. Civ. P. 23(a). And the proposed class must fit within one of the three types of permitted classes. /d. 23(b). All three requirements are met here. A. The settlement class is ascertainable The proposed settlement class consists of all investors, excluding Innocoll directors and officers, who purchased or acquired Innocoll stock between July 25, 2014 (the date of the IPO) and December 29, 2016 (the date that Innocoll announced that the FDA rejected its application) “and were damaged thereby.” Doc. No. 121-2, Stipulation of Settlement 1.38. These are “objective” and “administratively feasible” criteria for deciding who is in the class and who is not. Byrd, 784 F.3d at 163. Thus, the class is ascertainable. B. The settlement class satisfies all the prerequisites The proposed class also meets Rule 23’s prerequisites. First, the class is “so numerous that joinder of all members is impracticable.” Fed. R. Civ. P. 23(a)(1). Innocoll is a nationally traded

company, with thousands of shareholders during the relevant time period. Not all of those shareholders could practically join this suit as individuals, nor could they reasonably, efficiently, and economically mount their own individual suits. See In re Loewen Grp. Inc. Secs. Litig., 233 F.R.D. 154, 162 (E.D. Pa. 2005).

Second, the class shares “common” “questions of law or fact.” Fed. R. Civ. P. 23(a)(2). What did innovoll say about FDA approval of its medical device? Were those statements misleading? Did the CEO and Chief Medical Office know, or should they have known, that these statements were misleading? Did the statements affect the stock price? These “central” questions, more than suited for “class-wide resolution,” generate “common answers apt to drive the resolution of the litigation.” Wal-Mart Stores, Inc, v. Dukes, 564 U.S. 338, 350 (2011) (internal quotation marks omitted). Third, the class representatives’ claims are “typical of the claims ... of the class.” Fed. R. Civ. P. 23(a)(3). Both named representatives, Russel Bleiler and Carl Bayney, rely on the same legal theories and the same misrepresentations as all the other shareholders. /n re Schering Plough Corp. ERISA Litig., 589 F.3d 585, 598 (3d Cir. 2009). They inspire no “unique or atypical defenses to [their] claims.” /¢. Fourth, the class representatives “fairly and adequately protect the interests of the class.” Fed, R. Civ. P. 23(a)(4). The lead plaintiffs have no “possible conflict of interests” or special “incentives.” In re Schering, 589 F.3d at 602. Likewise, class counsel “are qualified and serve the interests of the entire class.” In re Gen. Motors, 55 F.3d at 801. In this case, the counsel are experienced in securities class actions and have vigorously prosecuted this case. C. The settlement class fits within Rule 23(b) Finally, the proposed class fits into one of the accepted “types” of class actions. Fed. R. Civ. P. 23(b).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Mullane v. Central Hanover Bank & Trust Co.
339 U.S. 306 (Supreme Court, 1950)
Basic Inc. v. Levinson
485 U.S. 224 (Supreme Court, 1988)
Erica P. John Fund, Inc. v. Halliburton Co.
131 S. Ct. 2179 (Supreme Court, 2011)
Wal-Mart Stores, Inc. v. Dukes
131 S. Ct. 2541 (Supreme Court, 2011)
In Re Linerboard Antitrust Litigation
292 F. Supp. 2d 631 (E.D. Pennsylvania, 2003)
In Re Lucent Technologies Inc., Securities Litigation
307 F. Supp. 2d 633 (D. New Jersey, 2004)
Crystal Byrd v. Aaron's Inc
784 F.3d 154 (Third Circuit, 2015)
In re Schering Plough Corp. Erisa Litigation
589 F.3d 585 (Third Circuit, 2009)
Sullivan v. DB Investments, Inc.
667 F.3d 273 (Third Circuit, 2011)
Karcich v. Stuart
194 F.R.D. 166 (E.D. Pennsylvania, 2000)
In re the Loewen Group Inc. Securities Litigation
233 F.R.D. 154 (E.D. Pennsylvania, 2005)
Chakejian v. Equifax Information Services, LLC
275 F.R.D. 201 (E.D. Pennsylvania, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
PEPICELLI v. INNOCOLL HOLDINGS PUBLIC LIMITED COMPANY, Counsel Stack Legal Research, https://law.counselstack.com/opinion/pepicelli-v-innocoll-holdings-public-limited-company-paed-2022.